Trial · NCT02338973
Interferon Gamma-1b Administered Topically for Macular Edema/Intraretinal Schisis Cysts in Rod-Cone Dystrophy (RCD) and Enhanced S-Cone Syndrome (ESCS)
NCT02338973, Phase 1, Phase 2, Terminated, National Eye Institute (NEI); results first posted 2019-08-06
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Interferon Gamma-1b Administered Topically for Macular Edema/Intraretinal Schisis Cysts in Rod-Cone Dystrophy (RCD) and Enhanced S-Cone Syndrome (ESCS). Trials, record NCT02338973. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02338973
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Interferon Gamma-1b Administered Topically for Macular Edema/Intraretinal Schisis Cysts in Rod-Cone Dystrophy (RCD) and Enhanced S-Cone Syndrome (ESCS)
- NCT number
- NCT02338973
- Status
- Terminated
- Phases
- Phase 1, Phase 2
- Enrollment
- 4 participants, actual
- Lead sponsor
- National Eye Institute (NEI)
- Conditions
- Inherited Ophthalmic Diseases, Inherited Retinal Degeneration
- Interventions
- Interferon gamma-1b
- First posted
- 2015-01-15
- Last updated
- 2019-08-13
- Results first posted
- 2019-08-06
Source ClinicalTrials.gov
Registered outcomes31
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number and Severity of IP-related AEs | Study duration, up to 52 weeks | The number and severity of adverse events related to the investigation product (IP). |
| Primary | Number of Participants Who Withdrew | Study duration, up to 52 weeks | The number of participants who withdrew early. |
| Secondary | Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 1 | Day 1 | Change in BCVA from baseline as compared to Day 1 by participant in both study and fellow eyes. |
| Secondary | Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 2 | Day 2 | Change in BCVA from baseline as compared to Day 2 by participant in both study and fellow eyes. |
| Secondary | Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 3 | Day 3 | Change in BCVA from baseline as compared to Day 3 by participant in both study and fellow eyes. |
| Secondary | Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 2 | Week 2 | Change in BCVA from baseline as compared to Week 2 by participant in both study and fellow eyes. |
| Secondary | Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 5 | Week 5 | Change in BCVA from baseline as compared to Week 5 by participant in both study and fellow eyes. |
| Secondary | Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 8 | Week 8 | Change in BCVA from baseline as compared to Week 8 by participant in both study and fellow eyes. |
| Secondary | Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 52 | Week 52 | Change in BCVA from baseline as compared to Week 52 by participant in both study and fellow eyes. |
| Secondary | Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 1 | Day 1 | Change in maximum subretinal fluid volume as measured on OCT from baseline as compared to Day 1 by participant in both study and fellow eyes. |
1 to 10 of 31Source ClinicalTrials.gov
See all 31 registered outcomesOutcomes31
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number and Severity of IP-related AEs | Study duration, up to 52 weeks | adverse events related to IP | NUMBER | |
| PRIMARY | Number of Participants Who Withdrew | Study duration, up to 52 weeks | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 1 | Day 1 | BCVA values are presented for Baseline and Day 1 and the change at Day 1 from Baseline for each participant (study and fellow eye). | letters read | NUMBER |
| SECONDARY | Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 2 | Day 2 | BCVA values are presented for Baseline and Day 2 and the change at Day 2 from Baseline for each participant (study and fellow eye). | letters read | NUMBER |
| SECONDARY | Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 3 | Day 3 | BCVA values are presented for Baseline and Day 3 and the change at Day 3 from Baseline for each participant (study and fellow eye). | letters read | NUMBER |
| SECONDARY | Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 2 | Week 2 | BCVA values are presented for Baseline and Week 2 and the change at Week 2 from Baseline for each participant (study and fellow eye). | letters read | NUMBER |
| SECONDARY | Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 5 | Week 5 | BCVA values are presented for Baseline and Week 5 and the change at Week 5 from Baseline for each participant (study and fellow eye). | letters read | NUMBER |
| SECONDARY | Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 8 | Week 8 | BCVA values are presented for Baseline and Week 8 and the change at Week 8 from Baseline for each participant (study and fellow eye). | letters read | NUMBER |
| SECONDARY | Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 52 | Week 52 | BCVA values are presented for Baseline and Week 52 and the change at Week 52 from Baseline for each participant (study and fellow eye). | letters read | NUMBER |
| SECONDARY | Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 1 | Day 1 | Subretinal Fluid Volume values are presented for Baseline and Day 1 and the change at Day 1 from Baseline for each participant (study and fellow eye). | mm^3 | NUMBER |
1 to 10 of 31Source ClinicalTrials.gov
See all 31 outcomesResults by group677
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number and Severity of IP-related AEs | Interferon Gamma-1b | Severity: Mild | 3 | adverse events related to IP | |
| Number and Severity of IP-related AEs | Interferon Gamma-1b | Severity: Severe | 1 | adverse events related to IP | |
| Number of Participants Who Withdrew | Interferon Gamma-1b | 0 | Participants | ||
| Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 1 | BCVA at Baseline in Study Eye | Participant 001 | 77 | letters read | |
| Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 1 | BCVA at Baseline in Fellow Eye | Participant 001 | 80 | letters read | |
| Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 1 | BCVA at Day 1 in Study Eye | Participant 001 | 76 | letters read | |
| Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 1 | BCVA at Day 1 in Fellow Eye | Participant 001 | 79 | letters read | |
| Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 1 | Difference in BCVA at Day 1 From Baseline in Study Eye | Participant 001 | -1 | letters read | |
| Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 1 | Difference in BCVA at Day 1 From Baseline in Fellow Eye | Participant 001 | -1 | letters read | |
| Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 1 | BCVA at Baseline in Study Eye | Participant 002 | 39 | letters read |
1 to 10 of 677Source ClinicalTrials.gov
See all 677 results by groupParticipant flow5
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Interferon Gamma-1b | 4 | |
| Overall Study | Rod-cone Dystrophy (RCD) | Interferon Gamma-1b | 2 | |
| Overall Study | Enhanced S-Cone Syndrome (ESCS) | Interferon Gamma-1b | 2 | |
| Overall Study | COMPLETED | Interferon Gamma-1b | 4 | |
| Overall Study | NOT COMPLETED | Interferon Gamma-1b | 0 |
Source ClinicalTrials.gov
Adverse events9
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Ocular Hyperaemia | Eye disorders | Interferon Gamma-1b | 1 | 4 | 1 |
| other | Lacrimation Increased | Eye disorders | Interferon Gamma-1b | 1 | 4 | 1 |
| other | Eye Pruritus | Eye disorders | Interferon Gamma-1b | 1 | 4 | 1 |
| other | Cystoid Macular Oedema | Eye disorders | Interferon Gamma-1b | 1 | 4 | 1 |
| other | Abdominal Pain | Gastrointestinal disorders | Interferon Gamma-1b | 1 | 4 | 1 |
| other | Back Pain | Musculoskeletal and connective tissue disorders | Interferon Gamma-1b | 1 | 4 | 1 |
| other | Retinal Telangiectasia | Eye disorders | Interferon Gamma-1b | 1 | 4 | 1 |
| other | Diabetic Retinopathy | Eye disorders | Interferon Gamma-1b | 1 | 4 | 1 |
| serious | Visual Acuity Reduced | Eye disorders | Interferon Gamma-1b | 1 | 4 | 1 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Interferon Gamma-1b | 0 | 4 |
| Total, other adverse events | Interferon Gamma-1b | 2 | 4 |
| Total, serious adverse events | Interferon Gamma-1b | 1 | 4 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02338973
GET https://conductscience.org/api/trials/v1/NCT02338973/registered?page=2